Vaccine trials require accurate drug supply forecasting and a dynamic supply chain to support sites in regions where virus prevalence changes quickly. That's why companies such as AstraZeneca save 10%+ annually from their drug supply budget by transforming forecasting and supply chain efficiency with Signant.
With hundreds or thousands of participants reporting symptoms for 7-14 days after vaccine intervention, trust Signant SmartSignals eCOA and our built-in reactogenicity diary to capture accurate, time-stamped data. Receive real-time alerts of potential adverse event indicators, and eliminate the costly transcription errors and delays inherent with paper.
Participants in vaccine trials must understand complex information and risks involved with your vaccine study. That's why we offer eConsent and Patient Concierge solutions alongside eCOA. This ensures patients fully understand their study commitment and keeps your trial top of mind to support adherence and completion.
Compliance and Retention
Global Supplies Management
Efficient Patient Data Capture
We know vaccine studies are often large and globally dispersed with sensitive timeframes, extended participant follow-up periods, multiphase designs, and critical data management needs. Leverage our Signant SmartSignals suite to navigate these challenges and gather the audit-ready, high quality evidence you need to get your vaccine to the public.